DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:DBD • US2536512021

71.88 USD
+2.53 (+3.65%)
Last: Feb 6, 2026, 12:49 PM
Fundamental Rating

4

Taking everything into account, DBD scores 4 out of 10 in our fundamental rating. DBD was compared to 34 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year DBD was profitable.
  • In the past year DBD had a positive cash flow from operations.
  • DBD had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • The Return On Assets of DBD (1.36%) is better than 67.65% of its industry peers.
  • DBD has a Return On Equity of 4.57%. This is in the better half of the industry: DBD outperforms 76.47% of its industry peers.
  • DBD's Return On Invested Capital of 8.85% is fine compared to the rest of the industry. DBD outperforms 70.59% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DBD is significantly below the industry average of 16.39%.
  • The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROIC 8.85%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • DBD has a Profit Margin of 1.37%. This is in the better half of the industry: DBD outperforms 67.65% of its industry peers.
  • Looking at the Operating Margin, with a value of 7.47%, DBD is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DBD has grown nicely.
  • DBD has a Gross Margin (25.48%) which is comparable to the rest of the industry.
  • DBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DBD is destroying value.
  • DBD has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DBD has been reduced compared to 5 years ago.
  • Compared to 1 year ago, DBD has an improved debt to assets ratio.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • DBD has an Altman-Z score of 1.97. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 1.97, DBD is doing good in the industry, outperforming 61.76% of the companies in the same industry.
  • The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 3.71, DBD is doing good in the industry, outperforming 67.65% of the companies in the same industry.
  • A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
  • DBD has a Debt to Equity ratio (0.84) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Altman-Z 1.97
ROIC/WACC0.93
WACC9.47%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
  • DBD has a Current ratio (1.36) which is comparable to the rest of the industry.
  • DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • DBD has a Quick ratio of 0.89. This is comparable to the rest of the industry: DBD outperforms 52.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 0.89
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for DBD have decreased strongly by -38.07% in the last year.
  • DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
  • DBD shows a decrease in Revenue. In the last year, the revenue decreased by -2.86%.
  • Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.21% on average over the next years. This is quite good.
  • Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.51% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.64, which indicates a rather expensive current valuation of DBD.
  • Based on the Price/Earnings ratio, DBD is valued a bit cheaper than the industry average as 73.53% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.67. DBD is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 14.62 indicates a correct valuation of DBD.
  • Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than 67.65% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of DBD to the average of the S&P500 Index (27.20), we can say DBD is valued slightly cheaper.
Industry RankSector Rank
PE 19.64
Fwd PE 14.62
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.12% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DBD is valued a bit cheaper than 79.41% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.25
EV/EBITDA 7.65
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
  • DBD's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.22
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DIEBOLD NIXDORF INC

NYSE:DBD (2/6/2026, 12:49:58 PM)

71.88

+2.53 (+3.65%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-05
Earnings (Next)02-12
Inst Owners105.4%
Inst Owner Change-0.73%
Ins Owners1.81%
Ins Owner Change-0.17%
Market Cap2.58B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (12.1%)
Short Float %2.32%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.72%
EPS NY rev (1m)0%
EPS NY rev (3m)12.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 19.64
Fwd PE 14.62
P/S 0.7
P/FCF 10.25
P/OCF 9.23
P/B 2.33
P/tB N/A
EV/EBITDA 7.65
EPS(TTM)3.66
EY5.09%
EPS(NY)4.92
Fwd EY6.84%
FCF(TTM)7.01
FCFY9.76%
OCF(TTM)7.79
OCFY10.84%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.22
PEG (5Y)N/A
Graham Number50.42
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROCE 11.2%
ROIC 8.85%
ROICexc 9.91%
ROICexgc 29.15%
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
FCFM 6.82%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Debt/EBITDA 2.28
Cap/Depr 20.59%
Cap/Sales 0.75%
Interest Coverage 2.89
Cash Conversion 68.06%
Profit Quality 497.23%
Current Ratio 1.36
Quick Ratio 0.89
Altman-Z 1.97
F-Score7
WACC9.47%
ROIC/WACC0.93
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%

DIEBOLD NIXDORF INC / DBD FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 4 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.